<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01228084</url>
  </required_header>
  <id_info>
    <org_study_id>6613</org_study_id>
    <secondary_id>SOL-10082-L</secondary_id>
    <secondary_id>6613</secondary_id>
    <nct_id>NCT01228084</nct_id>
  </id_info>
  <brief_title>Sulforaphane in Treating Patients With Recurrent Prostate Cancer</brief_title>
  <official_title>The Effects of Sulforaphane in Patients With Biochemical Recurrence of Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Wayne D. Kuni and Joan E. Kuni Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well sulforaphane works in treating patients with recurrent
      prostate cancer. Sulforaphane may prevent or slow the growth of certain cancers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the proportion of patients who achieve a 50% decline in prostate-specific
      antigen (PSA) levels within 20 weeks of sulforaphane treatment.

      SECONDARY OBJECTIVES:

      I. To determine the percentage change in PSA from baseline to the final measured value at the
      end of study as well as the maximal PSA decline that occurs while on study for each subject.

      II. To determine the proportion of patients whose PSA has not doubled after full 20 weeks of
      sulforaphane treatment.

      III. To determine the safety profile of sulforaphane. IV. To determine the pharmacokinetics
      (PK) of sulforaphane and its metabolites in blood.

      V. To determine the effect of sulforaphane supplementation on target pharmacodynamic (PD)
      modulation in peripheral blood cells.

      VI. To assess the effect of Glutathione-S-Transferase Mu 1 (GSTM1) genotype on sulforaphane
      PK, PD.

      VII. To collect frozen serum for future analysis of correlative biomarkers.

      OUTLINE:

      Patients receive sulforaphane orally (PO) once daily for 20 weeks in the absence of disease
      progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 14-30 days and every 6
      months for 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients Who Achieve a 50% Decline in Prostate-Specific Antigen (PSA) Levels</measure>
    <time_frame>Less than or equal to 20 weeks of sulforaphane treatment.</time_frame>
    <description>To determine the proportion of patients who achieve a decline in PSA levels while receiving sulforaphane treatment. as a measure of anti-tumor activity in men with recurrent prostate cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in PSA From Baseline to Final Measured Value at End of Study</measure>
    <time_frame>Measure at baseline and after stopping study treatment (less than or equal to 20 weeks of treatment with sulforaphane.)</time_frame>
    <description>To determine the percentage change in PSA from baseline to the final measured value at the end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Percent Change in PSA (i.e., the Smallest Increase for Those With Increased PSA and the Greatest Decline for Those With Decreased PSA)</measure>
    <time_frame>PSA measured every 28 days while on study treatment, an average of 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Whose PSA Levels Have Not Doubled</measure>
    <time_frame>While on treatment with sulforaphane (less than or equal to 20 weeks.)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade 3 or Higher Treatment Related Toxicity</measure>
    <time_frame>Continually through study and 14-30 days after last drug dose.</time_frame>
    <description>Toxicities will be graded based on the NIH Cancer Therapy Evaluation Program (CTEP) Common Toxicity Criteria of Adverse Events Version 4.0 (http://ctep.cancer.gov). All adverse events of any grade (for example, abnormal laboratory values, etc.) deemed clinically significant by the investigator will be recorded as a measure of the safety profile of sulforaphane</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of Sulforaphane (SFN) in Blood</measure>
    <time_frame>Day 1 of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of SFN in Blood Among Patients With Glutathione-S-Transferase Mu 1 (GSTM1) Null Genotype</measure>
    <time_frame>Day 1 of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of SFN in Blood Among Patients With Glutathione-S-Transferase Mu 1 (GSTM1) Intact Genotype</measure>
    <time_frame>Day 1 of study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Adenocarcinoma of the Prostate</condition>
  <condition>Recurrent Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Sulforaphane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulforaphane</intervention_name>
    <description>Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.</description>
    <arm_group_label>Sulforaphane</arm_group_label>
    <other_name>Broccoli Sprout Extract (BSE)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Sulforaphane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Sulforaphane</arm_group_label>
    <other_name>Pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopathologically or cytologically proven adenocarcinoma of the prostate treated
             with either a prostatectomy or definitive radiation (external beam or brachytherapy

          -  Protocol-Specific Prostate Working Group 2 (PCWG2) Criteria: rising PSA after
             definitive therapy

               -  For post surgical patients: the nadir reference value (#1) is the last PSA
                  measured before increases are documented, with subsequent values obtained a
                  minimum of 1 week apart; if the PSA at time point 3 (value #3A) is greater than
                  that at point 2, then eligibility has been met; if the PSA is not greater than
                  point 2 (value #3B), but value #4 is, the patient is eligible assuming that other
                  criteria are met and values 3A or #4 are 1.0 ng/mL or higher

               -  For post radiation therapy patients: the nadir reference value (#1) is the last
                  PSA measured before increases are documented, with subsequent values obtained a
                  minimum of 1 week apart; if the PSA at time point 3 (value #3A) is greater than
                  that at point 2, then eligibility has been met; if the PSA is not greater than
                  point 2 (value #3B), but value #4 is, the patient is eligible assuming that other
                  criteria are met and if values 3A or #4 are 2.0 ng/mL or more above the nadir
                  reference value (#1) according to Phoenix/American Society for Therapeutic
                  Radiology and Oncology (ASTRO) criteria

          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt;= 2

          -  The following laboratory results within 4 weeks prior to starting study treatment:

               -  White blood cells (WBC) &gt;= 3000/mm^3

               -  Neutrophil &gt;= 1,500/mm^3

               -  Platelet &gt;= 100,000/mm^3

               -  Serum creatinine =&lt; upper limit of normal (ULN)

               -  Albumin &gt; 3.0 gm/dL

               -  Total bilirubin &lt; 1.5 X ULN

               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 1.5 X ULN

               -  Testosterone level &gt;= 150ng/dL, and no evidence of progression while on prior
                  hormonal therapy, if applicable (i.e. patient must be non-castrate resistant).

          -  Prior androgen therapy is allowed as long as the patient did not progress while on
             therapy.

          -  The following imaging scans within 12 weeks prior to starting study treatment: Whole
             Body Bone Scan: computed tomography (CT) Chest/Abdomen/Pelvis w/ contrast; NOTE: if
             contrast medium for CT scan is contraindicated for the patient, documentation of this
             is required and a CT scan with contrast will not be required; subject still must
             obtain a CT without contrast, though.

          -  Willingness to use effective contraception by study participants or their female
             partners throughout the treatment period and for at least 2 months following treatment

          -  Signed informed patient consent and Health Insurance Portability and Accountability
             Act (HIPAA) within 3 months prior to starting treatment

        Exclusion Criteria:

          -  Significant active medical illness which in the opinion of the investigator would
             preclude protocol treatment

          -  Measurable and/or evaluable recurrent prostate cancer by imaging (CT scan of the
             chest, abdomen, and pelvis and bone scan performed within 12 weeks prior to starting
             treatment) or by physical exam

          -  Prior investigational therapy within 30 days prior to starting study treatment

          -  Prior treatment with a known histone deacetylase inhibitor (including but not limited
             to valproic acid, suberoylanilide hydroxamic acid [SAHA],Panobinostat (LBH589), etc)
             within 6 months prior to starting study treatment or while on study therapy

          -  Concurrent systemic treatment for prostate cancer

          -  Current treatment with warfarin

          -  Gastrointestinal ailments which would interfere with the ability to adequately absorb
             sulforaphane

          -  Allergy to cruciferous vegetables

          -  Any condition which, in the opinion of the study clinician, would make participation
             in the study harmful to the patient
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshi J Alumkal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2010</study_first_submitted>
  <study_first_submitted_qc>October 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2010</study_first_posted>
  <results_first_submitted>November 5, 2013</results_first_submitted>
  <results_first_submitted_qc>January 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 3, 2014</results_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Joshi Alumkal</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>sulforaphane</keyword>
  <keyword>broccoli sprout extract (BSE)</keyword>
  <keyword>prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>phase II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulforafan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sulforaphane</title>
          <description>Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sulforaphane</title>
          <description>Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.6" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients Who Achieve a 50% Decline in Prostate-Specific Antigen (PSA) Levels</title>
        <description>To determine the proportion of patients who achieve a decline in PSA levels while receiving sulforaphane treatment. as a measure of anti-tumor activity in men with recurrent prostate cancer.</description>
        <time_frame>Less than or equal to 20 weeks of sulforaphane treatment.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sulforaphane</title>
            <description>Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Who Achieve a 50% Decline in Prostate-Specific Antigen (PSA) Levels</title>
          <description>To determine the proportion of patients who achieve a decline in PSA levels while receiving sulforaphane treatment. as a measure of anti-tumor activity in men with recurrent prostate cancer.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in PSA From Baseline to Final Measured Value at End of Study</title>
        <description>To determine the percentage change in PSA from baseline to the final measured value at the end of study.</description>
        <time_frame>Measure at baseline and after stopping study treatment (less than or equal to 20 weeks of treatment with sulforaphane.)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sulforaphane</title>
            <description>Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in PSA From Baseline to Final Measured Value at End of Study</title>
          <description>To determine the percentage change in PSA from baseline to the final measured value at the end of study.</description>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="-32" upper_limit="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Percent Change in PSA (i.e., the Smallest Increase for Those With Increased PSA and the Greatest Decline for Those With Decreased PSA)</title>
        <time_frame>PSA measured every 28 days while on study treatment, an average of 5 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sulforaphane</title>
            <description>Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Percent Change in PSA (i.e., the Smallest Increase for Those With Increased PSA and the Greatest Decline for Those With Decreased PSA)</title>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="-71" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Whose PSA Levels Have Not Doubled</title>
        <time_frame>While on treatment with sulforaphane (less than or equal to 20 weeks.)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sulforaphane</title>
            <description>Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Whose PSA Levels Have Not Doubled</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Grade 3 or Higher Treatment Related Toxicity</title>
        <description>Toxicities will be graded based on the NIH Cancer Therapy Evaluation Program (CTEP) Common Toxicity Criteria of Adverse Events Version 4.0 (http://ctep.cancer.gov). All adverse events of any grade (for example, abnormal laboratory values, etc.) deemed clinically significant by the investigator will be recorded as a measure of the safety profile of sulforaphane</description>
        <time_frame>Continually through study and 14-30 days after last drug dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sulforaphane</title>
            <description>Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Grade 3 or Higher Treatment Related Toxicity</title>
          <description>Toxicities will be graded based on the NIH Cancer Therapy Evaluation Program (CTEP) Common Toxicity Criteria of Adverse Events Version 4.0 (http://ctep.cancer.gov). All adverse events of any grade (for example, abnormal laboratory values, etc.) deemed clinically significant by the investigator will be recorded as a measure of the safety profile of sulforaphane</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half-life of Sulforaphane (SFN) in Blood</title>
        <time_frame>Day 1 of study treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sulforaphane</title>
            <description>Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life of Sulforaphane (SFN) in Blood</title>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="1.8" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half-life of SFN in Blood Among Patients With Glutathione-S-Transferase Mu 1 (GSTM1) Null Genotype</title>
        <time_frame>Day 1 of study treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sulforaphane</title>
            <description>Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life of SFN in Blood Among Patients With Glutathione-S-Transferase Mu 1 (GSTM1) Null Genotype</title>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="2.0" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half-life of SFN in Blood Among Patients With Glutathione-S-Transferase Mu 1 (GSTM1) Intact Genotype</title>
        <time_frame>Day 1 of study treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sulforaphane</title>
            <description>Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life of SFN in Blood Among Patients With Glutathione-S-Transferase Mu 1 (GSTM1) Intact Genotype</title>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.8" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sulpforaphane</title>
          <description>Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE v4</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gatrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joshi Alumkal, MD</name_or_title>
      <organization>Oregon Health &amp; Science University, Knight Cancer Institute</organization>
      <phone>503-494-1091</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

